Immunotherapy for first-line metastatic melanoma in Slovenia
Part of Cancer, Skin clinical trials.
This study follows people with melanoma that has spread to other organs who are receiving immunotherapy as their first treatment. Researchers want to see how well this therapy works and look for clues in the body that predict response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- Your melanoma has spread to other parts of the body (metastatic melanoma).
- You are about to start your very first immunotherapy treatment for this melanoma.
- You are willing and able to sign a consent form to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial looks at whether adding a program of exercise and nutrition changes can improve quality of life and treatment outcomes for people with melanoma who are starting immunotherapy. If you qualify, you would take part in a structured plan to see if these lifestyle changes help.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.